Que recherchez-vous ?
Un contenu sur ce site
Une personne sur l'annuaire
Une formation sur le catalogue
Un contenu sur ce site
Une personne sur l'annuaire
Une formation sur le catalogue



The PHAR2 research unit (Inserm U1070 – University of Poitiers) has secured funding for two international collaborative projects, NEXCOL and RIPCORD, under the European Partnership on One Health Antimicrobial Resistance (EUP OHAMR) 2026 Joint Transnational Call.
Both projects aim to develop innovative therapeutic strategies against multidrug-resistant Gram-negative bacteria by optimising antibiotic combinations.
Coordinated by Prof. Frédéric Tewes (PHAR2), will explore nanotechnology-based formulations combining novel colistin derivatives with complementary antibiotics. By improving drug delivery and antibacterial activity, the project seeks to overcome resistance while reducing toxicity.
involving Dr. Julien Buyck (PHAR2) as a consortium partner, will investigate the combination of rifabutin and polymyxin B against carbapenem-resistant Gram-negative pathogens. The project will integrate microbiological investigations and pharmacokinetic/pharmacodynamic (PK/PD) approaches to optimise treatment efficacy and limit resistance emergence.
These two projects highlight PHAR2’s expertise in antimicrobial pharmacology, pharmaceutical formulation, and translational PK/PD research, while strengthening its international collaborations.
Discover the projects: Research Themes
Actualités et événements
Actualités et événements
Actualités et événements
Actualités et événements
Actualités et événements
Actualités et événements